At CView‑Consult, I support clinical research teams in developing innovative therapeutic solutions, driven by a deep conviction: scientific progress only matters when it truly improves patients’ lives. Passionate about science and closely connected to the realities of patient care, I bring my expertise to projects that require rigor, responsiveness, and a clear understanding of clinical challenges. My mission is simple and meaningful: to help accelerate the development of new treatment options, while ensuring quality, ethics, and safety at every step. Because behind every protocol, every dataset, and every study, there are people waiting for answers. And they are the reason I commit myself every day.
Évaluer mon protocole▪ OT4B (Ongoing since March 2025)
Support Phase 3 protocol writing and study set-up activities for a program in Prader Willi Syndrome.
▪ Synendos Therapeutics AG (July 2025-March 2026)
Supported the development of study protocol and start-up activities of early phase clinical trials in CNS indications (Anxiety – Tourette syndrome – Post traumatic stress disorder) with focus on early signal detection.
▪ Vico Therapeutics (February 2025 – April 2026)
▪ Protocol writing of a phase 2 clinical trial in Huntington Disease and support of clinical team on ad-hoc basis.
Managed and led a cross-functional team (statistics, bioanalytics, pharmacology, data management) for the lead asset Nizubaglustat from phase 1 to phase 3.
▪ Responsible for vendor management (selection, contract negotiation and budget control).
▪ Led clinical development plan discussions (with integrated biomarker strategy) and clinical study execution in EU, USA and LaTam.
▪ Responsible for protocols and study documents development for CTA submission, in multiple clinical phase studies.
Led clinical team to support the design of clinical development plan(s), with clinical phase 1 and 2 study design(s) in Multiple Sclerosis (BS-CD20, MAGLi), Alzheimer disease (Brain shuttle Gantenerumab) and Schizophrenia.
▪ Led collaboration meetings between pRED and Product Development group.
▪ Authored protocol for biomarker studies as part of biomarker strategy plan.
Supported medical lead in the development of program-level documents and collaborated on phase 3 protocol development in diabetic retinopathy with Lucentis.
▪ Study design, protocol, ICF, CSR writing, feasibility questionnaires, data management activities, Data cleaning, interpretation and reporting.
▪ Experience with small molecules, antibodies.
▪ Rare diseases (Pulmonary Hypertension, Huntington disease and Lysosomal disorders), Multiple Sclerosis, Alzheimer disease, Parkinson disease, schizophrenia and Age-Related Macular edema.
▪ (FDA, EMA and MHRA).
▪ Dossier for CTA submissions, Briefing books, Integrated safety summary, summary of clinical efficacy, ILAP documents.
▪ Cross-functional team leadership, mentoring junior scientists, managing scientific advisory Board.
▪ Presentations at webinars, family meetings and investigator meeting, scientific publications.
Integrated development plans
Biomarker‑driven strategies
Early signal detection
Cross‑functional scientific leadership
Protocol authoring (Phases 1–3, natural history studies)
Study rationale and design optimization
ICF, CRF, and charter development
Tailored designs for rare and CNS indications
Study start‑up coordination
Vendor selection and oversight
Scientific troubleshooting
Cross‑functional team alignment
CRF design and database specifications
Data cleaning and review
Interpretation of clinical, biomarker, and safety data
Support for interim analyses and reporting
CTA/IND preparation
Briefing books and scientific responses
Support for regulatory meetings
Integrated safety and efficacy summaries
Scientific presentations and training
Investigator meeting content
Patient‑advocacy communication
Support for publications and posters
Scientific sections of grant applications
Program‑level summaries
Strategic scientific storytelling